|3,3-二吲哚甲烷|CsnPharm

CAS No.: 1968-05-4

3,3'-Diindolylmethane/3,3'-亚甲基二吲哚 Catalog No. CSN19392

Synonyms: DIM;Arundine;HB 236

3,3'-Diindolylmethane is an AR structurally similar androgen receptor antagonist.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述3,3'-Diindolylmethane(DIM) is a strong, pure androgen receptor (AR) antagonist. DIM exhibits potent antiproliferative and antiandrogenic properties in androgen-dependent human prostate cancer cells. DIM suppresses cell proliferation of LNCaP cells and inhibits dihydrotestosterone (DHT) stimulation of DNA synthesis. Moreover, DIM inhibited endogenous PSA transcription and reduced intracellular and secreted PSA protein levels induced by DHT in LNCaP cells. Also, DIM inhibited, in a concentration-dependent manner, the DHT-induced expression of a prostate-specific antigen promoter-regulated reporter gene construct in transiently transfected LNCaP cells^[3]. DIM significantly inhibited the proliferation of human gastric cancer cells in a dose-dependent manner. The percentage of G1 phase cells increased 24 h following DIM treatment. DIM reduced CDK2, CDK4, CDK6 and cyclin D1 protein levels, while increasing p53 protein levels^[4]. After intraperitoneal injection of 3,3'-diindolylmethane, skin erythema and edema in mice were significantly alleviated. Furthermore, 3,3'-diindolylmethane reduced immune activation, probably by inhibiting the secretion of thymic stromal lymphopoietin by keratinocytes. 3,3'-Diindolylmethane also promoted the differentiation of regulatory T cells and inhibited the activation of T helper 2 and T helper 17 cells to reduce atopic dermatitis-related immune responses^[5].
临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02999399	Smoking	Not Applicable	Active, not recruiting	June 2019	United States, Minnesota ... more >> University of Minnesota Minneapolis, Minnesota, United States, 55455 Collapse <<
NCT02525159	Breast Cancer	Phase 3	Completed	-	-
NCT02197000	BRCA1 Gene Mutation ... more >> BRCA2 Gene Mutation Collapse <<	Not Applicable	Recruiting	September 2018	Israel ... more >> Rabin Medical Center, Beilinson Hospital Recruiting Petah-Tikva, Israel, 49100 Contact: Rachel Ozalvo +972(0)39376553 racheloz@clalit.org.il Principal Investigator: David Margel, M.D, PhD Principal Investigator: Rinat Yerushalmi, MD Collapse <<

更多
参考文献

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 4.0600 mL
- 20.2999 mL
- 40.5998 mL
- 5 mM
- 0.8120 mL
- 4.0600 mL
- 8.1200 mL
- 10 mM
- 0.4060 mL
- 2.0300 mL
- 4.0600 mL

技术信息

CAS号

1968-05-4

储存条件

粉末: Keep in dark place,Sealed in dry,Room Temperature

液体: -20°C:3-6 月 -80°C:12月

分子式

C17H14N2

运输

蓝冰

分子量

246.31

别名

DIM;Arundine;HB 236;3,3'-二吲哚甲烷

溶解度

DMSO	47.0 mg/mL (190.8 mM)
Water	Insoluble
Ethanol	16.0 mg/mL (65.0 mM)

动物实验配方

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02999399	Smoking	Not Applicable	Active, not recruiting	June 2019	United States, Minnesota ... more >> University of Minnesota Minneapolis, Minnesota, United States, 55455 Collapse <<
NCT02525159	Breast Cancer	Phase 3	Completed	-	-
NCT02197000	BRCA1 Gene Mutation ... more >> BRCA2 Gene Mutation Collapse <<	Not Applicable	Recruiting	September 2018	Israel ... more >> Rabin Medical Center, Beilinson Hospital Recruiting Petah-Tikva, Israel, 49100 Contact: Rachel Ozalvo +972(0)39376553 racheloz@clalit.org.il Principal Investigator: David Margel, M.D, PhD Principal Investigator: Rinat Yerushalmi, MD Collapse <<
NCT00591305	Papilloma	Not Applicable	Terminated(insufficient resour... more >>ce for recruitment) Collapse <<	-	United States, Massachusetts ... more >> Boston Medical Center Boston, Massachusetts, United States, 02118 Collapse <<
NCT00591305	-	-	Terminated(insufficient resour... more >>ce for recruitment) Collapse <<	-	-
NCT01846364	Proliferative Thyroid Disease	Early Phase 1	Terminated(Lack of sufficient ... more >>enrollment) Collapse <<	-	United States, New York ... more >> The New York Eye & Ear Infirmary New York, New York, United States, 10003 Collapse <<
NCT01022333	Breast Cancer	Phase 1	Unknown	December 2010	Canada, Ontario ... more >> Familial Breast Cancer Research Unit, Women's College Research Institute Recruiting Toronto, Ontario, Canada, M5G 1N8 Collapse <<
NCT00462813	Cervical Cancer ... more >> Precancerous Condition Collapse <<	Phase 3	Completed	-	United Kingdom ... more >> Barts and the London School of Medicine London, England, United Kingdom, EC1M 6BQ University Hospital of Wales Cardiff, Wales, United Kingdom, CF14 4XW Collapse <<
NCT00305747	Prostate Cancer	Phase 1	Completed	-	United States, Michigan ... more >> Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States, 48201-1379 Weisberg Cancer Treatment Center Detroit, Michigan, United States, 48334 Collapse <<
NCT00450229	Adenocarcinoma of the Prostate... more >> Prostate Cancer Stage I Prostate Cancer Stage II Prostate Cancer Collapse <<	Phase 1	Completed	-	United States, Wisconsin ... more >> University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 Collapse <<
NCT03152097	Kidney Diseases ... more >> Cardiovascular Diseases Collapse <<	Not Applicable	Recruiting	February 2019	United States, Pennsylvania ... more >> University of Pittsburgh Recruiting Pittsburgh, Pennsylvania, United States, 15261 Contact: Alexander J Prokopienko, PharmD AJPROKOP@pitt.edu Collapse <<
NCT00784394	Healthy, no Evidence of Diseas... more >>e Collapse <<	Phase 1	Completed	-	United States, Kansas ... more >> University of Kansas Medical Center Kansas City, Kansas, United States, 66160 Collapse <<
NCT00392652	Healthy, no Evidence of Diseas... more >>e Collapse <<	Phase 1	Completed	-	United States, Kansas ... more >> University of Kansas Medical Center Kansas City, Kansas, United States, 66160 Collapse <<
NCT00888654	Prostate Cancer	Phase 2	Completed	-	United States, Michigan ... more >> Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States, 48201-1379 Josephine Ford Cancer Center at Henry Ford Hospital Detroit, Michigan, United States, 48202 Collapse <<
NCT00212381	Cervical Dysplasia	Phase 3	Completed	-	United States, New York ... more >> NYU School of Medicine New York, New York, United States, 10016 Collapse <<
NCT00888654	-	-	Completed	-	-
NCT01391689	Stage IA Breast Cancer ... more >> Stage IB Breast Cancer Stage II Breast Cancer Stage IIIA Breast Cancer Collapse <<	Not Applicable	Completed	-	United States, Arizona ... more >> Arizona Cancer Center Tucson, Arizona, United States, 85012 Collapse <<
NCT01612910	Breast Cancer Female	Phase 2	Withdrawn(Research cancelled.)	-	-
NCT02483624	SLE	Phase 1	Terminated	-	-

3,3'-Diindolylmethane/3,3'-亚甲基二吲哚 Catalog No. CSN19392

靶点选择性

请登录您的专属账户

确认信息